Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853298)
Watch
English
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
scientific article
Resensitization to Crizotinib by the LorlatinibALKResistance Mutation L1198F
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
26698910
retrieved
13 November 2016
title
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
(English)
1 reference
stated in
PubMed
PubMed ID
26698910
retrieved
13 November 2016
main subject
lorlatinib
1 reference
stated in
ChEBI release 2020-05-28
ChEBI ID
143117
crizotinib
1 reference
based on heuristic
inferred from title
author
Gad Getz
series ordinal
21
0 references
Luc Friboulet
object named as
Luc Friboulet
series ordinal
2
0 references
Ignaty Leshchiner
object named as
Ignaty Leshchiner
series ordinal
3
0 references
Ryohei Katayama
object named as
Ryohei Katayama
series ordinal
17
0 references
A John Iafrate
series ordinal
18
object named as
A John Iafrate
0 references
Jeffrey A Engelman
series ordinal
23
object named as
Jeffrey A Engelman
0 references
author name string
Alice T Shaw
series ordinal
1
0 references
Justin F Gainor
series ordinal
4
0 references
Simon Bergqvist
series ordinal
5
0 references
Alexei Brooun
series ordinal
6
0 references
Benjamin J Burke
series ordinal
7
0 references
Ya-Li Deng
series ordinal
8
0 references
Wei Liu
series ordinal
9
0 references
Leila Dardaei
series ordinal
10
0 references
Rosa L Frias
series ordinal
11
0 references
Kate R Schultz
series ordinal
12
0 references
Jennifer Logan
series ordinal
13
0 references
Leonard P James
series ordinal
14
0 references
Tod Smeal
series ordinal
15
0 references
Sergei Timofeevski
series ordinal
16
0 references
Long Le
series ordinal
19
0 references
Michele McTigue
series ordinal
20
0 references
Ted W Johnson
series ordinal
22
0 references
language of work or name
English
0 references
publication date
7 January 2016
0 references
published in
The New England Journal of Medicine
0 references
volume
374
0 references
page(s)
54-61
0 references
issue
1
0 references
cites work
Rociletinib in EGFR-mutated non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Q27690215
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Ceritinib in ALK-rearranged non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Ponatinib in refractory Philadelphia chromosome-positive leukemias
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
20 March 2017
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
7 April 2017
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
29 September 2017
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
29 September 2017
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
29 September 2017
Anchored multiplex PCR for targeted next-generation sequencing.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
27 November 2018
Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
27 November 2018
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4773904
retrieved
27 November 2018
Identifiers
DOI
10.1056/NEJMOA1508887
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560018
OpenCitations bibliographic resource ID
560018
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560018
PMCID
4773904
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560018
PubMed ID
26698910
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560018
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
